Prevention of Post-STEMI Left Ventricular Thrombus With Optimized Anticoagulant (EARLYmyo-LVT Ⅱ)
Status:
Not yet recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
Left ventricular thrombus is a common complication subsequent to ST-segment elevation
myocardial infarction (STEMI) that related to increased embolic events. This study aims to
assess the efficacy and safety outcomes of Rivaroxaban on the prevention of post-STEMI left
ventricular thrombus.